Rocket Science Health validates targeted olfactory-cleft deposition in non-human primates ahead of the 4th Nasal Formulation & Delivery Summit
Author: Rocket Science Health
Methylene blue dye demonstrating laminar fluid localized olfactory deposition.
The "how" of drug delivery is becoming as strategically critical as the "what," driving a shift toward innovative routes of administration—such as the intranasal delivery of vaccines and therapeutics—to bypass systemic barriers and improve patient outcomes.
Rocket Science Health is at the forefront of this shift, having recently achieved a pivotal milestone: demonstrating that its proprietary intranasal device technology successfully targets the olfactory cleft in non-human primates (NHP).
Since the olfactory cleft provides a unique, non-invasive "right-of-way" for direct-to-brain administration, this successful NHP data serves as a vital bridge toward human commercialization, validating the device’s ability to achieve precise, reproducible dosing in the most challenging regions of the nasal anatomy.
About Rocket Science Health:
Rocket Science Health, founded by Canadian business leader Kenneth Irving, develops precision drug delivery technologies focused on brain-targeted therapeutics and vaccines. Our needle-free intranasal device enables non-clinical self-administration for at-home care, emergency rescue, and mass immunization. Its fluidics are specifically engineered for today's delicate biologics and dose-dependent drugs. As a team, we are driven to create innovations that expand access to care—especially for under-resourced communities and for individuals who face physical, cognitive, or challenging care environments where thoughtful design can improve health outcomes.
